04 Nov Decompression Sickness: What the Research Says About Ascent Rates and Safety Stops
Diving Safety Notice: Decompression sickness is a medical emergency. If you or a dive buddy develop joint or muscle pain, numbness, weakness, dizziness, trouble breathing, confusion, or unusual fatigue after a dive, give 100% oxygen if available and trained to do so, call local emergency services, and contact the Divers Alert Network (DAN) 24/7 Emergency Hotline at +1-919-684-9111. Do not wait to see whether symptoms improve. This content is for general information only and is not medical advice or a substitute for dive training. Follow the guidance of your training agency, dive computer, and a diving medicine physician. Products and companies linked in this post are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Decompression sickness is one of the main safety concerns of scuba diving. It occurs when inert gas (usually nitrogen) that has dissolved in the body's tissues and blood forms bubbles as the surrounding pressure drops during or after ascent. While depth and bottom time are key factors, research has also shown that the way a diver returns to the surface can affect decompression stress.
Controlling ascent rate and making shallow safety stops are therefore central to modern guidance. Both are used to reduce unnecessary decompression stress and give the body extra time to eliminate dissolved gas; neither can completely eliminate the risk of decompression sickness.
Dr. Parekh[/caption]
Ankit Parekh, PhD
Director of the Sleep And Circadian Analysis (SCAN) Group
Assistant Professor of Medicine
(Pulmonary, Critical Care and Sleep Medicine)
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Sleep apnea is associated with incident cardiovascular disease, and is a common chronic condition affecting over a billion people worldwide. In diagnosing and treating sleep apnea, it is imperative to establish the type of sleep apnea—whether it is obstructive or central sleep apnea. The differential contribution of central vs. obstructive sleep apnea toward incidental cardiovascular disease in those with significant sleep apnea has not been well studied.
Our group has developed an automated algorithm that deduces on a breath-by-breath level whether reductions in airflow are predominantly due to obstructive or central phenomena. Our algorithm uses several features that are known to be key in distinguishing the type of events and derives a probability of obstruction across each “small” (reduced amplitude) breath. The breath-by-breath probability is then used to determine whether a patient’s burden of sleep apnea is predominantly obstructive or central.
In this work, we analyzed sleep study data from The Osteoporotic Fractures in Men (MrOS) cohort (N=2793) consisting of elderly men, across two visits separated on average by 6.5 years, and derived the probability of obstruction on a breath-by-breath level. The median probability of obstruction for each subject was computed and analyzed against outcomes of cardiovascular disease. We also assessed the stability of the metric in those without any prevalent cardiovascular disease. We find that median probability of obstruction was stable across the two visits, and those with any incident cardiovascular disease had a lower median probability of obstruction: patients with incident cardiovascular outcomes had a significant burden of sleep apnea that was predominantly “central” in nature.
Dr. Han[/caption]
Meilan K Han MD, MS
Henry Sewall Professor of Medicine
Professor of Internal Medicine and Section Head
Division of Pulmonary and Critical Care Medicine, Medical School
University of Michigan
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In the NIH sponsored SPIROMICS study we demonstrated that symptomatic, tobacco exposed individuals have frequent exacerbations. Many of these individuals are treated with the same inhaled medications that have shown benefit in COPD, but we don’t have any evidence basis for this practice.
Dr. Dunietz[/caption]
Galit Levi Dunietz MPH, PhD
Assistant Professor
Dr. Braley[/caption]
Dr. Garantziotis[/caption]
Stavros Garantziotis MD
Division of Intramural Research
National Institute of Environmental Health Sciences
Research Triangle Park, NC
MedicalResearch.com: What is the background for this study? How does hyaluronan differ from other medications for COPD? Is it used for other medical conditions?
Response: Hyaluronan is a natural sugar found in the human body, including in the lung. We have found that when the lungs are exposed to pollution, this sugar breaks down, and the breakdown fragments cause inflammation in the lung. We also found that if we give back the natural form of hyaluronan, it protects the lung from inflammation. Patients suffering from COPD also have a lot of hyaluronan breakdown in their lungs. We therefore reasoned, that giving them back the natural form of hyaluronan, as an inhalation treatment, would help them reduce inflammation. We tested this, as a first step, in the treatment acute inflammation of the lungs in COPD patients who are suffering an exacerbation of their disease.
Hyaluronan is different from existing medications in that it is a natural product of the body. It is used in Europe for conditions like cystic fibrosis, and after sinus surgery to humidify the airways. Because it is given by inhalation, it acts locally in the lungs.
Dr. Conway Morris[/caption]
Dr Andrew Conway Morris
Wellcome Trust Clinical Research Career Development Fellow
University of Cambridge
Hon Consultant in Intensive Care Medicine
Addenbrookes Hospital, Cambridge
MedicalResearch.com: What is the background for this study?
Response: Patients with COVID-19 frequently need to come to the intensive care unit (ICU), where we use mechanical ventilation to support their lungs as they get over the intense inflammation caused by the virus. During the first wave of the virus we noted that a lot of our patients appeared to be developing secondary infections (infections they didn’t have when they came into the ICU).
We therefore rolled out a rapid diagnostic test for these secondary bacterial infections that we had developed previously, and this study reports the use of this diagnostic and also describes the types of bacteria seen. To see if the increase in secondary infections was due to COVID specifically, we compared them to patients who were managed in the same ICU but who did not have COVID.
Dr. Trudo[/caption]
Frank Trudo, MD MBA
Vice President, US Medical Affairs
Respiratory & Immunology
AstraZeneca
MedicalResearch.com: What is the background for this study?
Response: ETHOS was a randomized, double-blinded, multi-center, parallel-group, 52-week trial to assess the efficacy and safety of PT010 in symptomatic patients with moderate to very severe COPD and a history of exacerbation(s) in the previous year. A subset of patients participated in the 4-hour pulmonary function test (PFT) sub-study, with the following primary endpoints: change from baseline in morning pre-dose trough FEV1 at Week 24 at (both doses of budesonide/glycopyrrolate/formoterol fumarate MDI versus glycopyrrolate/formoterol fumarate MDI), and FEV1 area under the curve from 0-4 hours at Week 24 (both doses of budesonide/glycopyrrolate/formoterol fumarate MDI vs budesonide/formoterol fumarate MDI).
Dr. Trudo[/caption]
Frank Trudo, MD MBA
Vice President, US Medical Affairs
Respiratory & Immunology
AstraZeneca
MedicalResearch.com: What is the background for this study?
Response: ETHOS is a randomized, double-blinded, multi-center, parallel-group, 52-week trial to assess the efficacy and safety of PT010 in symptomatic patients with moderate to very severe COPD and a history of exacerbation(s) in the previous year. Outcomes in the ETHOS trial included, as a primary endpoint, the rate of moderate or severe exacerbations.
MedicalResearch.com: How does PT010 differ from other treatments for COPD?
Dr. Alladina[/caption]
Jehan Alladina MD
Massachusetts General Hospital
Pulmonary and Critical Care Medicine
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: During the pandemic, clinicians around the world have shared anecdotal experiences to help inform care of patients with COVID-19. However, these anecdotes and observations, without careful analysis, can bias clinicians; many clinicians have even recommended experimental therapies based on this information alone.
To that end, the goal of our study was to rigorously examine the respiratory failure experienced by critically ill patients with COVID-19 and understand their response to the standards of care for respiratory failure.